The Latest Breaking News from Disease

MUMBAI: More than 62% patients admitted to the SevenHills Hospital, Andheri for Covid-19 are fully vaccinated, indicating that majority could be affected with the Omicron variant of Sars-Cov2 that is known for its ability to evade immunity from vaccines. The high vaccine penetration, though, is perhaps the reason why most…

A world-leading system developed in Japan to detect liver cancer is to be introduced in Thailand, where the disease is a major health issue.

In an exclusive interview with Io Dodds, Dr Anthony Fauci looks back on his decades-long career in public health

Vertex Pharmaceuticals (NASDAQ: VRTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate inaxaplin (VX-147) for the treatment of patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

The UK Health Security Agency (UKHSA) has confirmed a total of 321 monkeypox cases in the UK, as of June 7, with 305 in England, 11 in Scotland, three in Wales and two in Northern Ireland

Precision BioSciences Inc (NASDAQ:DTIL) shared new interim data from the Phase 1/2a study of PBCAR0191 for the patient population with aggressive lymphomas. The data demonstrated that PBCAR0191 produced high clinical response rates in CAR T relapsed patients who received a median of five prior lines of therapy.  Evaluable subjects in the study had…

Stealth BioTherapeutics (NASDAQ: MITO) presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.

Aldeyra Therapeutics Inc's (NASDAQ:ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer test responder proportions after a single day of dosing.  The Schirmer test,…

Immunovant Inc (NASDAQ:IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED).  Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected to enroll about 100 subjects for each trial.  Topline…